Physician profile
Benjamin Chang
NPI 1598756793
$3,175.10
in general payments reported to CMS, 2019-2025
26 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $489 · 2021: $172 · 2022: $374 · 2023: $668 · 2024: $444 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.10 | 2022-2025 | Ozurdex, Durysta |
| Alcon Vision LLC | $375.02 | 2019-2025 | Clareon, Clareon Panoptix Pro, Simbrinza |
| Carl Zeiss Meditec, INC. | $358.60 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $290.35 | 2022-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $241.74 | 2022-2025 | Xipere, Vyzulta, Visudyne |
| Biotissue Holdings INC. | $241.26 | 2023-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $156.37 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $118.40 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $104.63 | 2023-2025 | Syfovre |
| Glaukos Corporation | $100.37 | 2019 | |
| Inspire Medical Systems, INC. | $97.05 | 2023 | Inspire |
| Sun Pharmaceutical Industries INC. | $85.44 | 2019-2023 | Cequa, Xelpros |
| Mallinckrodt Hospital Products INC. | $78.27 | 2022 | |
| Horizon Therapeutics Plc | $74.18 | 2019-2022 | |
| Harrow Eye, LLC | $67.95 | 2024-2025 | Vevye |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $66.90 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $38.10 | 2022-2023 | Vabysmo |
| Oyster Point Pharma, INC. | $38.09 | 2023-2024 | Tyrvaya |
| Allergan, INC. | $36.04 | 2020 | |
| Novartis Pharmaceuticals Corporation | $35.16 | 2021-2023 | |
| Rxsight INC | $29.46 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $28.02 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.91 | 2021 | |
| Ocular Therapeutix, INC. | $19.42 | 2023 | Dextenza |
| Astellas Pharma US INC | $18.65 | 2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $14.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.